PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Wang, Jingshi ^a   Wang, Yini ^a   Wu, Lin ^a   Zhang, Jia ^a   Lai, Wenyuan ^a   Wang, Zhao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Epstein Barr virus; Hemophagocytic lymphohistiocytosis; PEG aspargase

Indexed keywords

AMYLASE; ASPARAGINASE MACROGOL; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; ASPARAGINASE; CISPLATIN; MACROGOL DERIVATIVE; PREDNISONE; VIRUS DNA;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMYLASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CHILD; CLINICAL FEATURE; CONDITIONING; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HLA TYPING; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PANCREATITIS; PHENOTYPE; REFRACTORY EPSTEIN BARR VIRUS ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SEX DIFFERENCE; SURVIVAL TIME; THROMBOCYTE COUNT; WHOLE BODY RADIATION; BLOOD; CLINICAL TRIAL; COMPLICATION; EPSTEIN BARR VIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; REMISSION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CISPLATIN; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDNISONE; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84986905138     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0317-7     Document Type: Article

References (24)

1. Maakaroun NR, Moanna A, Jacob JT, Albrecht T. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93-105.
2. Zeng X, Wei N, Wang Y, Wang J, Zhang J, Wu L, et al. Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Zhonghua Xue Ye Xue Za Zhi. 2015;36(6):507-10 (Article in Chinese).
3. Henter JI, Samuelsson-Horne A, Aricó M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-73.
4. Imashuku S, Teramura T, Tauchi H, Ishida Y, Otoh Y, Sawada M, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica. 2004;89(2):183-8.
5. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673-86.
6. Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186-92.
7. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31.
8. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44(3):259-72.
9. Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with Alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-9.
10. Shiraishi A, Ohga S, Doi T, Ishimura M, Takimoto T, Takada H, et al. Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012;59(2):265-70.
11. Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221(5):278-85.
12. Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ. Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer. 2009;53(2):184-90.
13. Fox CP, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O'Connor N, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010;51(1):66-9.
14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75-82.
15. Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19(10):2665-73.
16. Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, et al. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol. 2003;41(2):103-9.
17. Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54(2):299-306.
18. Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, Neven B, Picard C, Blanche S, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-8.
19. Henzan T, Nagafuji K, Tsukamoto H, Miyamoto T, Gondo H, Imashuku S, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59-61.
20. Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376-82.
21. Imashuku S, Kudo N, Kubo K, Yachie A. Are regimens containing rituximab effective in the initial treatment of Epstein-Barr virus-positive natural killer cell lymphoproliferative disease-associated hemophagocytic lymphohistiocytosis? Int J Hematol. 2013;98(3):375-7.
22. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005;130(6):860-8.
23. Jinta M, Imadome K, Komatsu H, Yoshimori M, Kurata M, Fujiwara S, et al. L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: a pilot study. J Med Dent Sci. 2015;62(1):1-9.
24. Ahn JS, Rew SY, Shin MG, Kim HR, Yang DH, Cho D, et al. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2010;85(9):719-22.